ATR and Alzheimer disease: Hou et al. (2014), evaluated the efficacy of SS on AD. Oral administration of SS ameliorates cognitive impairment in AD transgenic mice, reduces Aβ levels, delays Aβ amyloidosis, and reduces Aβ-induced brain gliosis and neuronal loss in AD mice. Consistently, SS treatment reduced amyloid-related motor dysfunction and premature death in AD transgenic flies. Mechanistic studies show that ATR exerts neuroprotective effects on anti-bodies and plays a role in the treatment of AD (Table 7).